Active substances
Omeprazole + Sodium bicarbonate
- SFDA 10
- US FDA 22
- US price lines 3
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| Byraza Plus | 40,1100 mg,mg | Capsule · Oral use | 28 Blister | SAR 87.50 | Generic · Prescription | Alrazi Pharmaceutical Industries Factory Co | Valid |
| Byraza Plus | 20,1100 mg,mg | Capsule, hard · Oral use | 28 Blister | SAR 43.75 | Generic · Prescription | Alrazi Pharmaceutical Industries Factory Co | Valid |
| GASTROZOLE PLUS 20 MG/1100 MG CAPSULE | 20,1100 mg,mg | Capsule · Oral use | 28 Bottle | SAR 50.15 | Generic · Prescription | RIYADH PHARMA | Valid |
| GASTROZOLE PLUS 40/1100 MG CAPSULES | 40,1100 mg,mg | Capsule · Oral use | 28 Bottle | SAR 114.00 | Generic · Prescription | RIYADH PHARMA | Valid |
| OMIZ PLUS 20MG CAPSULE | 20,1100 mg,mg | Capsule · Oral use | 28 Blister | SAR 52.80 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Valid |
| OMIZ PLUS 40MG CAPSULE | 40,1100 mg,mg | Capsule · Oral use | 28 Blister | SAR 120.10 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Valid |
| Omeprex Plus | 40,1100 mg,mg | Capsule · Oral use | 30 Blister | SAR 93.75 | Generic · Prescription | SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO | Valid |
| Omezyn Plus | 40,1100 mg,mg | Capsule, hard · Oral use | 28 Blister | SAR 92.65 | Generic · Prescription | OMAN PHARMACEUTICAL PRODUCTS | Valid |
| Risek Plus | 40,1100 mg,mg | Capsule · Oral use | 30 Bottle | SAR 89.20 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Valid |
| SoiCarby | 40,1100 mg,mg | Capsule, hard · Oral use | 28 Blister | SAR 87.50 | Generic · Prescription | ALPHA PHARMA INDUSTRY | Valid |
Indications — CHI Daman Drug Formulary
BACTRIAL INFECTIONS OF THE GASTROINTESTINAL TRACT- H-PYLORI ERADICATION-EVIDENCE BASED FIRST LINE TREATMENT STRATEGY; BACTRIAL INFECTIONS OF THE GASTROINTESTINAL TRACT- H-PYLORI ERADICATION-SALVAGE THERAPIES; BARIATRIC SURGERY; DYSPEPSIA; GASTROESOPHAGEAL REFLUX DISEASE (GERD); MIGRAINE/ HEADACHE; PEPTIC ULCER
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| ZEGERID OTC | 20MG;1.1GM | capsule · oral | RILEY CONSUMER | Over-the-counter | 1 Dec 2009 |
| OMEPRAZOLE AND SODIUM BICARBONATE | 20MG/PACKET;1.68GM/PACKET; 40MG/PACKET;1.68GM/PACKET | for suspension · oral | STRIDES PHARMA INTL | Prescription | 19 Apr 2013 |
| ZEGERID OTC | 20MG/PACKET;1.68GM/PACKET | for suspension · oral | RILEY CONSUMER | Over-the-counter | 17 Jun 2013 |
| OMEPRAZOLE AND SODIUM BICARBONATE | 20MG;1.1GM | capsule · oral | PERRIGO R AND D | Over-the-counter | 15 Jul 2016 |
| OMEPRAZOLE AND SODIUM BICARBONATE | 20MG;1.1GM; 40MG;1.1GM | capsule · oral | DR REDDYS | Prescription | 15 Jul 2016 |
| OMEPRAZOLE AND SODIUM BICARBONATE | 20MG;1.1GM; 40MG;1.1GM | capsule · oral | AJANTA PHARMA LTD | Prescription | 15 Jul 2016 |
| OMEPRAZOLE AND SODIUM BICARBONATE | 20MG/PACKET;1.68GM/PACKET; 40MG/PACKET;1.68GM/PACKET | for suspension · oral | AJANTA PHARMA LTD | Prescription | 27 Jul 2016 |
| OMEPRAZOLE AND SODIUM BICARBONATE | 20MG;1.1GM; 40MG;1.1GM | capsule · oral | AUROLIFE PHARMA LLC | Prescription | 19 Aug 2016 |
| OMEPRAZOLE AND SODIUM BICARBONATE | 20MG;1.1GM | capsule · oral | AUROBINDO PHARMA | Over-the-counter | 7 Nov 2016 |
| OMEPRAZOLE AND SODIUM BICARBONATE | 20MG;1.1GM; 40MG;1.1GM | capsule · oral | SCIEGEN PHARMS | Prescription | 6 Dec 2016 |
| OMEPRAZOLE AND SODIUM BICARBONATE | 20MG;1.1GM | capsule · oral | ZYDUS | Over-the-counter | 16 Mar 2018 |
| OMEPRAZOLE AND SODIUM BICARBONATE | 20MG;1.1GM; 40MG;1.1GM | capsule · oral | ZYDUS PHARMS | Prescription | 25 May 2018 |
| OMEPRAZOLE AND SODIUM BICARBONATE | 20MG;1.1GM; 40MG;1.1GM | capsule · oral | ADAPTIS | Prescription | 30 Apr 2020 |
| KONVOMEP | 2MG/ML;84MG/ML | for suspension · oral | AZURITY | Prescription | 30 Aug 2022 |
| OMEPRAZOLE AND SODIUM BICARBONATE | 20MG/PACKET;1.68GM/PACKET | for suspension · oral | DR REDDYS | Over-the-counter | 9 May 2024 |
| OMEPRAZOLE AND SODIUM BICARBONATE | 20MG/PACKET;1.68GM/PACKET; 40MG/PACKET;1.68GM/PACKET | for suspension · oral | NOVITIUM PHARMA | Prescription | 10 Dec 2025 |
| ZEGERID | 20MG/PACKET;1.68GM/PACKET **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 40MG/PACKET;1.68GM/PACKET **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | for suspension · oral | SALIX | Discontinued | 15 Jun 2004 |
| ZEGERID | 40MG/PACKET;1.68GM/PACKET | for suspension · oral | SANTARUS | Discontinued | 21 Dec 2004 |
| ZEGERID | 20MG;1.1GM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 40MG;1.1GM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | capsule · oral | SALIX | Discontinued | 27 Feb 2006 |
| OMEPRAZOLE AND SODIUM BICARBONATE | 20MG;1.1GM; 40MG;1.1GM | capsule · oral | STRIDES PHARMA INTL | Discontinued | 25 May 2010 |
| OMEPRAZOLE AND SODIUM BICARBONATE | 20MG;1.1GM | capsule · oral | STRIDES PHARMA INTL | Discontinued | 15 Jul 2016 |
| OMEPRAZOLE AND SODIUM BICARBONATE | 20MG;1.1GM | capsule · oral | CHARTWELL RX | Discontinued | 15 Jul 2016 |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | KONVOMEP 2-84 MG/ML ORAL SUSP | $2.085 | per ML | 23 Sep 2026 |
| US NADAC | KONVOMEP 2-84 MG/ML ORAL SUSP | $1.762 | per ML | 23 Sep 2026 |
| US NADAC | KONVOMEP 2-84 MG/ML ORAL SUSP | $1.2442 | per ML | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.